Patents by Inventor Maria Frank-Kamenetsky

Maria Frank-Kamenetsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 9771591
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: September 26, 2017
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • Compositions and Methods for Inhibition of PCSK9 Genes
    Publication number: 20160354404
    Abstract: The invention relates to sirens targeting a PCs gene, and methods of using sirens to inhibit expression of PCs and to treat PCs related disorders, e.g., hyperlipidemia.
    Type: Application
    Filed: March 16, 2016
    Publication date: December 8, 2016
    Inventors: Gregory Hinkle, Maria Frank-Kamenetsky, Kevin Fitzgerald
  • Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
    Publication number: 20160348117
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Application
    Filed: January 25, 2016
    Publication date: December 1, 2016
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Dual Targeting siRNA Agents
    Publication number: 20160312216
    Abstract: The invention relates to dual targeting siRNA agents targeting a PCSK9 gene and a second gene, and methods of using dual targeting siRNA agents to inhibit expression of PCSK9 and to treat PCSK9 related disorders, e.g., hyperlipidemia.
    Type: Application
    Filed: October 16, 2015
    Publication date: October 27, 2016
    Inventors: Kevin Fitzgerald, Maria Frank-Kamenetsky, Klaus Charisse
  • ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160186180
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Application
    Filed: March 14, 2016
    Publication date: June 30, 2016
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 9322018
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: April 26, 2016
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • Compositions and methods for inhibiting expression of the PCSK9 gene
    Patent number: 9260718
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: February 16, 2016
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor Kotelianski
  • METHODS FOR INCREASING EFFICACY OF LIPID FORMULATED siRNA
    Publication number: 20160024498
    Abstract: This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that lowers LDL receptor levels.
    Type: Application
    Filed: April 30, 2015
    Publication date: January 28, 2016
    Applicant: TEKMIRA PHARMACEUTICALS CORPORATION
    Inventors: Kevin Fitzgerald, Maria Frank-Kamenetsky, Akin Akinc, Martin A. Maier
  • PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160017335
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene, and methods of using such RNAi agents to inhibit expression of PCSK9 and methods of treating subjects having a lipid disorder, such as a hyperlipidemia.
    Type: Application
    Filed: December 5, 2013
    Publication date: January 21, 2016
    Inventors: Anna Borodovsky, Rajeev G. Kallanthottathil, Kevin Fitzgerald, Maria Frank-Kamenetsky, William Querbes, Martin Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Muthiah Manoharan, Stuart Milstein
  • Dual targeting siRNA agents
    Patent number: 9187746
    Abstract: The invention relates to dual targeting siRNA agents targeting a PCSK9 gene and a second gene, and methods of using dual targeting siRNA agents to inhibit expression of PCSK.9 and to treat PCSK.9 related disorders, e.g., hyperlipidemia.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: November 17, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Maria Frank-Kamenetsky, Klaus Charisse
  • Methods for increasing efficacy of lipid formulated siRNA
    Patent number: 9051567
    Abstract: This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that increases LDL receptor levels.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: June 9, 2015
    Assignee: Tekmira Pharmaceuticals Corporation
    Inventors: Kevin Fitzgerald, Maria Frank-Kamenetsky, Akin Akinc, Martin A. Maier
  • iRNA Agents Targeting VEGF
    Publication number: 20150011608
    Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
    Type: Application
    Filed: July 7, 2014
    Publication date: January 8, 2015
    Inventors: Antonin de Fougerolles, Maria Frank-Kamenetsky, Muthiah Manoharan, Kallanthottathil Rajeev, Philipp Hadwiger
  • Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
    Publication number: 20140350075
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Application
    Filed: July 14, 2014
    Publication date: November 27, 2014
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor Kotelianski
  • Small organic molecule regulators of cell proliferation
    Patent number: 8852937
    Abstract: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. 32 and 33. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: October 7, 2014
    Assignee: Curis, Inc.
    Inventors: Anthony David Baxter, Edward Andrew Boyd, Maria Frank-Kamenetsky, Oivin Guicherit, Jeffery Porter, Stephen Price, Lee Rubin, John Harry Alexander Stibbard
  • Compositions and methods for inhibiting expression of the PCSK9 gene
    Patent number: 8809292
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: August 19, 2014
    Assignee: Alnylam Pharmaceuticals, Inc
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20140179768
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 26, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • Compositions And Methods For Inhibiting Expression Of The PCSK9 Gene
    Publication number: 20130331430
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene.
    Type: Application
    Filed: May 15, 2012
    Publication date: December 12, 2013
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Compositions and Methods for Inhibition of PCSK9 Genes
    Publication number: 20130289094
    Abstract: The invention relates to siRNAs targeting a PCSK9 gene, and methods of using siRNAs to inhibit expression of PC-SK9 and to treat PCSK9 related disorders, e.g., hyperlipidemia.
    Type: Application
    Filed: October 31, 2011
    Publication date: October 31, 2013
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Maria Frank-Kamenetsky, Kevin Fitzgerald
  • Dual Targeting siRNA Agents
    Publication number: 20130184324
    Abstract: The invention relates to dual targeting siRNA agents targeting a PCSK9 gene and a second gene, and methods of using dual targeting siRNA agents to inhibit expression of PCSK.9 and to treat PCSK.9 related disorders, e.g., hyperlipidemia.
    Type: Application
    Filed: September 22, 2010
    Publication date: July 18, 2013
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Maria Frank-Kamenetsky, Klaus Charisse
  • iRNA Agents Targeting VEGF
    Publication number: 20130018085
    Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Inventors: Antonin de Fougerolles, Maria Frank-Kamenetsky, Muthiah Manoharan, Kallanthottathil G. Rajeev, Philipp Hadwiger